What is Actually Recruiting Right Now
A quick scan of active studies shows two clear trends. First, drug developers are racing to refine the newest weight-loss-and-glucose drug class. Second, device companies are finally bringing automated insulin delivery to the type 2 population, which has historically been underserved by pump and algorithm technology.
The CAPTAIN-T2D trial (NCT07296484) from Sparrow Pharmaceuticals is worth a close look if you have type 2 diabetes that refuses to budge. It tests clofutriben, an HSD-1 inhibitor that targets elevated cortisol, which researchers believe drives insulin resistance in some hard-to-treat patients. The trial is running across 60 U.S. locations, from Chandler, Arizona, to Northridge, California, and plans to enroll about 1,500 participants in a 24-week double-blind treatment phase.
Another notable study is Ribupatide Phase 3 (NCT07284901), a once-weekly injectable for adults living with obesity or overweight plus diabetes. It began enrollment in January 2026, with sites spread across Oklahoma, Texas, Tennessee, Rhode Island, and South Carolina. Participation runs through early 2028, and the trial compares four different doses against placebo.
On the device side, Sequel Med Tech presented pivotal data on its twiist automated insulin delivery system at the ADA 86th Scientific Sessions in New Orleans. Results showed A1c improvements of 0.7 percentage points on average, time-in-range climbing from 57% to 73%, and no severe hypoglycemia events over 13 weeks. The system is not yet on the market, but the data suggest a meaningful option is heading toward review.
Who Should Consider Joining a Trial
The eligibility screen is where most people get tripped up, so it helps to know what researchers are looking for.
If you are 18 to 70 and already on insulin therapy, the next-generation Omnipod algorithm study (NCT07039981) is actively recruiting. It accepts both current pump users and people on basal-bolus or premix regimens who are willing to transition to pump therapy.
If you are living with overweight or obesity and type 2 diabetes, the ribupatide trial may be a fit, provided you have not used a GLP-1 receptor agonist, tirzepatide, or other weight-loss medication within the past three months. That washout window is a common exclusion, so review your medication history before applying.
If your diabetes is paired with chronic kidney disease, the Proact study at UCLA and other sites is evaluating REACT/rilparencel injections in adults aged 30 to 80 with both conditions. Renal involvement excludes you from most mainstream metabolic trials, so this one fills a real gap.
If your A1c stays elevated despite multiple medications, the GRADE study results, published from a long-running comparative effectiveness trial, still shape how doctors choose between common glycemia-lowering drugs combined with metformin. The trial itself has completed, but its findings influence which arms newer studies compare against.
Realistic Costs, Compensation, and Commitment
Compensation varies widely by trial, study phase, and visit burden. A type 1 diabetes diet study at Boston Children's Hospital, for example, compensates participants up to $1,300 for their time and provides all meals through a delivery service. Late-phase drug trials often offer similar ranges, though not every study pays. Ask the study coordinator directly what the compensation structure covers, whether travel is reimbursed, and whether parking is included.
| Trial | Focus | Typical Commitment | What to Expect |
|---|
| CAPTAIN-T2D | Cortisol-linked hard-to-treat T2D | 24-week treatment plus 4-week follow-up | Monthly visits, fasting labs, study drug |
| Ribupatide Phase 3 | Obesity with diabetes, weekly injection | Through early 2028 | Weekly injections, periodic A1c and weight checks |
| Omnipod next-gen algorithm | Insulin-requiring T2D, ages 16–70 | Multiple algorithm testing cycles | Pump training, CGM wear, frequent data uploads |
| Proact (REACT) | T2D with chronic kidney disease | Injection series, follow-up visits | Renal function monitoring, safety labs |
| twiist AID pivotal | Insulin-treated T2D | 13-week core phase | Automated delivery system, CGM, quarterly A1c |
One detail people overlook: the FDA does not set compensation rates for trials, and sponsors design payment schedules independently. Some studies pay per completed visit, others pay a lump sum at the end. A few offer nothing beyond the study drug and monitoring, which is still valuable if you are uninsured or underinsured and struggling to afford newer medications. Clinical trial participation is not "free treatment" in the promotional sense, but it does provide access to investigational therapies and close medical monitoring that would otherwise carry significant out-of-pocket cost.
How to Find and Evaluate a Nearby Trial
Start with ClinicalTrials.gov, which lets you filter by condition, location, and recruiting status. Search "type 2 diabetes" plus your state, then narrow to studies that are "recruiting" rather than "active, not recruiting." The site lists contact details for study coordinators at each location, so you can reach out directly.
University research pages are another reliable route. UCLA, for instance, lists 18 active type 2 diabetes studies on its researcher profiles page, eight of them open to eligible participants. The University of Wisconsin is running the ENRxICH study in Madison, which tests pharmacist-led medication management combined with community health worker support for people with uncontrolled diabetes.
Before you commit, ask the coordinator four questions. What is the exact randomization ratio, meaning your chance of receiving the active drug versus placebo? What does the visit schedule look like in the first month, since that is usually the heaviest? Who covers the cost of the study drug and lab work, and is there any scenario where you would be billed? And what happens at the end of the trial if the treatment proves effective for you, including any open-label extension or transition plan?
The Regional Angle
Trial access is not evenly distributed across the country. California hosts the largest cluster of metabolic research sites, concentrated in Los Angeles, Long Beach, Fountain Valley, and Huntington Park. Texas runs a close second, with active recruiting in Amarillo, Brownsville, El Paso, and DeSoto. Arizona has steady enrollment through Arizona Clinical Trials locations in Chandler and Tucson. If you live in a rural state, check neighboring metropolitan areas, because several of these studies list 40 or more U.S. locations, and sponsors often cover or reimburse travel for long-distance participants.
The twiist data presented in New Orleans is a reminder that geography also shapes how quickly new options reach patients. Trials conducted in the South, where diabetes prevalence runs higher than the national average, carry particular weight in showing how automated insulin delivery performs in real-world American conditions.
Making the Decision
A clinical trial is not a guarantee, and the placebo question deserves honest thought. If you are struggling with A1c, insurance barriers, or side effects from current medications, a trial can give you supervised access to options you cannot get through normal channels. The monitoring alone, with regular labs, CGM data, and specialist review, often improves diabetes control regardless of which arm you land in.
The research landscape is shifting fast. Automated insulin delivery is finally moving into type 2 diabetes, the cortisol pathway is being tested as a treatment target, and the GLP-1 class keeps expanding with new molecules and dosing schedules. None of that reaches your doctor's office without volunteers. If you meet the eligibility criteria, the next step is a phone call to a study coordinator listed on ClinicalTrials.gov. Ask the questions above, compare two or three options, and bring the printed study summary to your endocrinologist for a second opinion before you sign.
研究の知恵